MREO vs. WVE, IMCR, ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, and OCUL
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Wave Life Sciences (WVE), Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
Mereo BioPharma Group vs.
Mereo BioPharma Group (NASDAQ:MREO) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership.
In the previous week, Wave Life Sciences had 7 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 19 mentions for Wave Life Sciences and 12 mentions for Mereo BioPharma Group. Wave Life Sciences' average media sentiment score of 0.99 beat Mereo BioPharma Group's score of 0.11 indicating that Wave Life Sciences is being referred to more favorably in the news media.
Mereo BioPharma Group has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500.
Mereo BioPharma Group has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Mereo BioPharma Group's return on equity of 0.00% beat Wave Life Sciences' return on equity.
Wave Life Sciences received 314 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 80.00% of users gave Mereo BioPharma Group an outperform vote while only 67.78% of users gave Wave Life Sciences an outperform vote.
Mereo BioPharma Group presently has a consensus target price of $7.71, suggesting a potential upside of 216.16%. Wave Life Sciences has a consensus target price of $22.60, suggesting a potential upside of 137.57%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Mereo BioPharma Group is more favorable than Wave Life Sciences.
62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 4.1% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Mereo BioPharma Group has higher earnings, but lower revenue than Wave Life Sciences.
Summary
Mereo BioPharma Group beats Wave Life Sciences on 10 of the 17 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
This page (NASDAQ:MREO) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy MREO Stock Free MREO Stock Alerts